Sulfamethoxazole/trimethoprim
Phase 1Small molecule
Sulfamethoxazole/trimethoprim is one of 30 small molecule programs targeting Abscess. It is currently in Phase 1.
1
Indications
6
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
35 competitors in Abscess
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Valtrex
GGlaxo Dba Glaxosmithkline
Approved
Bactroban
PPadagis LLC
Approved
Duragesic
CCephalon
Approved
Flagyl
DDePuy Orthopaedics
Approved
Zyvox
PfizerPhase 3
Lamprene
NovartisPhase 3
Biaxin
AbbViePhase 3
Primaxin
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pneumonia1 trial
A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000727·322 enrolled
Randomized Controlled Trial1 trial
Multiple Myeloma1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]
- [4]
Details